Phosphatase and tensin homolog expression related to cetuximab effects in colorectal cancer patients: A meta-analysis

Table 2 Description of phosphatase and tensin homolog status

No.	Title of the study	Method
1	Analysis of PTEN, BRAF and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer	IHC
2	PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients	FISH
3	PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer	IHC
4	PTEN status in advanced colorectal cancer treated with cetuximab	FISH
5	PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies	IHC
6	PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients	IHC
7	Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study	FISH
8	Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer	IHC

PTEN: Phosphatase and tensin homolog; BRAF: V-raf murine sarcoma viral oncogene homolog; EGFR: Epidermal growth factor receptor; IHC: Immunohistochemistry; FISH: Fluorescence in situ hybridization.